Lonvoguran ziclumeran

Hereditary angioedema is estimated to affect 1 in 50,000 people worldwide. Symptoms commonly begin in childhood and worsen during puberty. Intestinal attacks cause abdominal symptoms, and airway swelling can be life-threatening. A systematic review reported mean or median diagnostic delays ranging from 3.9 to 26 years. A multinational adult survey reported a mean of 11.5 attacks during the preceding six months, with a standard deviation of 14.2. These findings describe different populations and should not be treated as estimates from one cohort.

In HAELO, the lonvo-z and placebo groups included 52 and 28 participants, respectively. During weeks 5–28, mean monthly attack rates were 0.26 and 2.10, corresponding to an 87% reduction with lonvo-z. The proportions without attacks were 62% and 11%. The between-group difference in change in AE-QoL score was -17.04 points. Through week 28, infusion-related reactions occurred in 32 of 52 participants (62%) receiving lonvo-z and 5 of 28 (18%) receiving placebo. No serious treatment-emergent adverse events or events of grade 3 or higher were reported in the lonvo-z group during that period.

HAELO provides evidence of reduced attack frequency compared with placebo. The reported median follow-up of 7.5 months does not establish lifetime durability or exclude uncommon delayed adverse effects. Cross-trial comparisons do not establish comparative effectiveness against active prophylactic treatments. The FDA accepted the BLA for Priority Review with a target action date of March 10, 2027; application acceptance is not marketing approval.